Wall Street brokerages expect that OncoSec Medical Inc (NASDAQ:ONCS) will report earnings per share (EPS) of ($0.18) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for OncoSec Medical’s earnings. OncoSec Medical reported earnings per share of ($0.24) in the same quarter last year, which indicates a positive year over year growth rate of 25%. The company is expected to announce its next earnings results on Friday, April 19th.
According to Zacks, analysts expect that OncoSec Medical will report full-year earnings of ($0.61) per share for the current financial year, with EPS estimates ranging from ($0.65) to ($0.56). For the next fiscal year, analysts expect that the business will post earnings of ($0.65) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for OncoSec Medical.
A number of research analysts have recently weighed in on ONCS shares. Zacks Investment Research raised shares of OncoSec Medical from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a research note on Friday, March 15th. Maxim Group reissued a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a research note on Monday, April 1st. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $3.13.
Shares of ONCS traded down $0.01 during mid-day trading on Friday, reaching $0.57. 473,168 shares of the company’s stock were exchanged, compared to its average volume of 633,565. OncoSec Medical has a 52-week low of $0.42 and a 52-week high of $1.96.
OncoSec Medical Company Profile
OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.
Read More: What Are Treasury Bonds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.